Hans Bishop, Grail CEO (Victor J. Blue/Bloomberg via Getty Images)
September 16, 2020 11:21 AM EDTUpdated 11:56 AM
Deals
R&D

For­get the IPO, Il­lu­mi­na is near­ing a buy­out of $1.9B liq­uid biop­sy start­up Grail — re­port

Jason Mast

Editor

Grail, the $1.9 bil­lion, Jeff Be­zos-backed liq­uid biop­sy start­up, may not be go­ing pub­lic af­ter all.

Wednes­day morn­ing, a week af­ter the biotech

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump’s sci­ence crack­down hits rare dis­ease med­i­cine: ‘We need to sit down with Elon Musk’

Lil­ly joins mol­e­c­u­lar glue field with Mag­net deal worth up to $1.25B

Pfiz­er vet William Pao’s next ven­ture; Sanofi’s com­pu­ta­tion­al sci­ence ex­ec leaves

Can Bill An­der­son save Bay­er?

Bridge­Bio on­col­o­gy spin­out to go pub­lic via com­bi­na­tion with SPAC from Cor­morant and Bi­hua Chen

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times